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“I knew exactly what to do. But in a much more real sense, I had no idea what to do.” – 





POPULAR SCIENCE SUMMARY OF THE THESIS 
Our immune system is busy around-the-clock with keeping us safe from bacteria, viruses, and 
even internal threats such as tumor cells. In the central nervous system, which consists of the 
brain and the spinal cord, specialized immune cells called microglia take over the important 
part of being the body’s guard. Microglia are already produced and in place during early 
development and have a vast variety of functions throughout life. This can range from 
maintenance, to dealing with a stroke, and even clearing out dead cells. Researchers found out 
decades ago that microglia can respond to different challenges by changing and adapting 
rapidly and with high plasticity, but to this day it is still not fully understood how these changes 
are controlled on a molecular level. We often call these changes the acquisition of an activated 
state. 
Broadly speaking, there are two commonly researched activation states – pro- and anti-
inflammatory activation. Pro-inflammatory activation often happens after events such as the 
invasion of pathogens. The microglia create an inflammatory microenvironment with the goal 
of combatting defective or damaging cells or components. On the other hand, anti-
inflammatory microglia are, for example, beneficial for tissue repair after injury. In the aging 
brain, these functions can be significantly impaired or delayed, which in turn is thought to 
contribute to neurodegenerative diseases such as Alzheimer’s or Parkinson’s disease. We are 
therefore interested in finding mechanisms that control inflammatory microglia and in 
understanding their role in the aging brain. 
Microglia also play an important role in brain tumors. Tumor cells attract microglia and 
reprogram them into a tumor-supportive phenotype. Instead of fighting off the malignant cells, 
microglia will help the tumor grow and invade more tissue. An additional part of this highly 
complex interplay are macrophages. These cells can be described as the counterpart of 
microglia outside of the central nervous system, they migrate into the brain and toward the 
tumor site, where their presence is associated with a worse clinical prognosis. We want to 
understand more about the interaction of these three cell types, what triggers the microglia or 
macrophages to become pro-tumoral and how to leverage this knowledge to find novel 
therapeutic options in the field of brain tumor research. 
As you can now hopefully appreciate, microglia are involved in almost every aspect of brain 
health. It is therefore crucial to understand what drives microglia into their activation states, 
and what lessons we can learn to ultimately advance clinical research for the benefit of current, 







In this thesis I aim to present our ongoing efforts to elucidate activation states and how these 
are regulated in microglia cells. An extensive body of work is dedicated to understanding how 
these resident immune cells can acquire certain activation states, as their roles are crucial for a 
great range of functions in the central nervous system – from homeostasis to pathological 
occurrences. In summary, the work presented here underlines the importance of microglia cells 
in the context of inflammation, aging, and the tumor microenvironment. 
In project I we identify a possible mechanism of regulation in microglia activation. Under 
normal circumstances, microglia are highly plastic and respond to a variety of stimuli in their 
microenvironment by drastically altering their transcriptome. As a result, cells acquire a pro-
inflammatory phenotype after exposure to lipopolysaccharides. ATG7, the autophagy-related 
protein 7, is known to play a vital role in the formation of autophagosomes. Here, we show 
how the deficiency of Atg7 significantly impacts the ability of microglia to respond to 
inflammatory stimuli on a transcriptional, as well as on a functional level. This effect was found 
to be attributed to reduced NF-κB-dependent signaling, which was demonstrated by impaired 
NF-κB nuclear translocation. 
In project II we investigate microglia in the context of the aging brain. Aging is often 
accompanied by cellular senescence, which can be characterized by growth arrest, a 
senescence-associated altered secretion of cytokines, mitochondrial dysfunction, and apoptosis 
resistance. Cells with a senescent phenotype are often associated with areas of age-related 
pathology, and in aged microglia this can lead to, for example, accumulation of protein 
aggregates and altered response to neuroinflammatory stimuli. With long-term cultivation of 
microglia, we show that these cells do not enter age-associated proliferative senescence but 
present with a distinct transcriptomic state and altered response to inflammatory stimuli. 
In project III we show that targeting the H3K27 histone methyltransferase, EZH2, in microglia 
can affect the invasion and cell death of pediatric glioma. Diffuse midline glioma H3K27M 
mutant, formerly known as diffuse intrinsic pontine glioma (DIPG), is associated with poor 
prognosis. This led to studies using EZH2 as a potential therapeutic target. Inhibition of EZH2 
in vivo by other groups showed reduced tumor growth and extended survival, however in vitro 
studies carried out by us, and others, showed limited effects of EZH2 inhibitors on tumor 
growth and survival. Here, we present that the inhibition of EZH2 in microglia leads to a robust 
anti-tumoral microglial activation state reducing tumor cell migration and increasing 
microglia-mediated cell death and phagocytosis of tumor cells, highlighting the tumor 
microenvironment (TME) as a potential target for further research on glioma treatments. 
In project IV we study the interplay of macrophages and microglia in the glioma 
microenvironment. Infiltrating and resident immune cells in the context of brain tumors are 
often grouped together as glioma-associated microglia/macrophages (GAMs). In this context, 
they are known to acquire phenotypes beneficial for tumor growth and progression, which 
makes them a particularly interesting subject researching treatment targets. Glioblastomas 
 
 
carrying a mutation in an isocitrate dehydrogenase (IDH1) are known to have better clinical 
prognosis, and less infiltration of GAMs. Here, we show that the presence of macrophages 
impacts the tumor migration as well as the acquisition of an activated microglia phenotype.  
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1.1 Physiology and function of microglia  
1.1.1 Microglia origins 
Microglia are the tissue-resident immune cells of the central nervous system (CNS). Pio Del 
Río-Hortega, a student of Santiago Ramón y Cajal, was the first to name this “third element” 
of the CNS microglia (Sierra et al., 2016). The term stems from the Greek micro (small) and 
glia (glue), as opposed to the other two elements being neuronal cells and neuroglia, or 
astrocytes. With the development of their histopathological staining techniques, they already 
hypothesized in the 1930’s the microglia’s phagocytotic abilities and their overall role in 
maintaining homeostasis (Rio-Hortega, 1939), laying an important foundation to today's 
research. Since then, these specialized macrophages have been the focus of immense research 
leading to thousands of published articles.  
The ontogeny of microglia was long debated, with an initial hypothesis from Río-Hortega 
himself postulating a mesodermal origin (Sierra et al., 2016). More recent studies found that 
microglia in mice originate from distinct progenitor cells in the embryonic yolk sac (YS) 
(Ginhoux et al., 2010). Through fate mapping experiments, the authors show that the pool of 
microglia, once established, is not significantly affected by circulating monocytes and suggest 
an ontogenically well-defined population. These YS progenitors circulate in the embryo during 
a short developmental time window, and populate tissues to form the basis of the innate 
immune system (Stremmel et al., 2018). The YS hypothesis of the origin of microglia has also 
been shown in zebrafish (Herbomel et al., 2001) and quails (Cuadros et al., 1993), suggesting 
an evolutionarily conserved mechanism. Circulating monocytes and other bone marrow-
derived cells, in either steady-state or even during inflammation, are additionally described as 
a less significant source of post-natal microglia, as reviewed in detail elsewhere (Ginhoux et 
al., 2013).  
1.1.2 Homeostatic functions 
The role of microglia in the developing, healthy brain has many facets, such as impacting the 
amount of neuronal precursor cells (NPC) via phagocytosis in the sub-ventricular zone (SVZ) 
(Cunningham et al., 2013). Their main contribution to CNS development is protecting and 
shaping the microenvironment. Other work has shown how endogenous microglia can regulate 
not only cortical precursor cells, but also astrocytes. A knockout mouse model using PU.1−/− 
animals, which have a lack of microglia, showed decreased proliferation of the precursor cells, 
as well as decreased astrogenesis (Antony et al., 2011). Microglia have also been found to play 
a significant role in the maturation of synapses, contributing to synaptic pruning by engulfment 
of synaptic material (Paolicelli et al., 2011). This process of maintaining certain synapses and 
pruning others is crucial for brain development. Different groups have hypothesized that 
synaptic engulfment is mediated by the complement pathway, which is classically involved in 




al. showed that C1q- and C3b-tagged (activated form of complement 3) synapses are likely 
phagocytosed by microglia, which express the C3 receptor, and are therefore contributing to 
synaptic maintenance in the CNS (Stevens et al., 2007). An alternative explanation was 
recently published by Nguyen et al., showing that synaptic plasticity can be promoted through 
remodeling of the extracellular matrix (ECM) (Nguyen et al., 2020). In the hippocampus, the 
brain region responsible for memory formation and consolidation of memory, neurons were 
shown to secrete interleukin-33 (IL-33). This IL-33-mediated neuron-microglia signaling was 
shown to impact the formation of new synapses as well as memory precision, measured by 
contextual fear discrimination. The same work further showed that the observed synaptic 
plasticity was likely due to microglia engulfing ECM components. Within the hippocampus, 
microglia have also been shown to be involved in the formation of learning-dependent synapses 
through brain-derived neurotrophic factor (BDNF) (Parkhurst et al., 2013), the differentiation 
of NPCs (Aarum et al., 2003), or the regulation of spatial memory and even altered social 
behaviors (Torres et al., 2016). Overall, these findings strongly suggest an impact of microglia 
on important memory functions in the healthy brain. 
During normal development, fractalkine signaling and the release of trophic factors by 
microglia, such as insulin-like growth factor 1 (IGF1), are involved in supporting neuronal 
survival (Ueno et al., 2013). During early postnatal development, microglial CD11b, as well as 
the DAP12/TREM2 pathway, are required for neuronal homeostasis (Wakselman et al., 2008). 
CD11b, together with CD18, forms the complement receptor 3 that is involved in phagocytosis 
through the complement signaling cascade. Microglia also contribute to normal neuronal 
apoptosis through the production of reactive oxygen species (ROS). ROS in high 
concentrations can become cytotoxic by oxidizing cellular components and molecules and its 
associated cell damage is also reported to be involved in aging and neurodegenerative diseases. 
Apart from this detrimental effect, ROS has also been shown to be involved in neuronal and 
synaptic plasticity, connectivity, or other processes in neuronal development (Oswald et al., 
2018). In an evolutionary conserved mechanism, microglia have also been shown to initiate 
apoptosis and finally engulf Purkinje cells, likely as part of developmentally programmed cell 
death (Marı́n-Teva et al., 2004). Lastly, the removal of cellular debris after apoptosis is part of 
the homeostatic functions of microglia. This phagocytic approach, which does not induce an 
inflammatory reaction, is mediated via a complex interplay of so called “find me”, “eat me” or 
“don’t eat me” signals and through receptors such as CX3CR1, triggering receptor expressed 
on myeloid cells 2 (TREM2) or SIGLEC, respectively (Butler et al., 2021). Clearing the CNS 
of debris, dying or dead cells is an important homeostatic function of these resident 
phagocytotic cells. 
1.1.3 Common microglia markers 
Markers that were found in early research to characterize microglia under steady-state 
conditions were, among others, CD45, CD11b, MHC class I and class II. Other general cell 
markers are further cluster of differentiation receptors such as CD68, CD80 or colony 




CX3CR1, as well as ionized calcium binding adaptor molecule 1 (IBA1) (Jurga et al., 2020). 
Fractalkine/CX3CR1 signaling in particular is important during developmental time windows 
of synaptic pruning, and CX3CR1-deficient mice present with impaired neuronal circuit 
integrity, regulation of neuronal precursor cells and neurogenesis (Kierdorf & Prinz, 2013). 
Many of the above-mentioned markers however are not specific to microglia or can be 
upregulated in microglia upon activation. This can present a challenge when trying to 
differentiate microglia from, for example, infiltrating macrophages. To discriminate between 
the different cell types, it can be useful to consider the amount of a certain marker protein 
expressed. For example, CD45 is also present on other monocytes and expressed at a higher 
level compared to microglia under steady-state conditions, although it should be noted the 
expression of this marker can also increases with microglia activation (Butovsky & Weiner, 
2018; Masliah et al., 1991). TMEM119, a transmembrane protein of currently unknown 
function, and P2RY12, a purinoceptor, are commonly described as unique markers for 
microglia cells (Bennett et al., 2016; Butovsky et al., 2014), see also figure 1. However, more 
recent work has challenged this view, suggesting that the activation of microglia alters and 
downregulates the expression of homeostatic microglia signature genes (DePaula-Silva et al., 
2019). Comparisons to other tissue-resident macrophages found that genes encoding for 
proteins such as SIGLEC-H, TREM2, and transcription factors like jun-B, jun-D or SALL1 
maintain microglia identity in the microenvironment of the CNS (Buttgereit et al., 2016, p. 1; 






1.2 Microglia activation  
1.2.1 Inflammatory activation states 
Such a variety of functions in a highly complex and plastic environment as the developing or 
adult brain presupposes that microglia are capable of responding to a long list of challenges 
including injury, inflammation, or tumors. In traumatic CNS injury, microglia rapidly respond 
and migrate towards the lesion site, where they have been reported to contribute to secondary 
injury events by exacerbating an inflammatory reaction, recruiting more immune cells to the 
injury site and releasing pro-inflammatory cytokines (Dusart & Schwab, 1994). Long-term 
microglia activation due to traumatic injury can lead to chronic effects and can even be seen in 
humans, posing a potential risk for post-traumatic neurodegeneration (Gentleman et al., 2004). 
Using Cx3cr1
GFP/+ mice with green fluorescent protein (GFP)-expressing microglia, a fast 
chemotactic response towards a two-photon laser ablation showcased the plasticity of their 
processes reacting to an injury site (Davalos et al., 2005). The same work furthermore showed 
that individual cells could even react towards multiple laser ablation sites nearby, and that their 
response is mediated through extracellular adenosine triphosphate (ATP). Other publications 
support these findings by demonstrating how purinergic receptor P2RY12, which are key 
players in ATP-mediated signaling, are crucial for directional process extension as well as 
migration (Haynes et al., 2006), and how microglia processes are triggered by ATP-mediated 
neuron-microglia communication (Dissing-Olesen et al., 2014). This remarkable plasticity and 
the ability to undergo structural changes based on their environment or challenge is one of the 
cells’ hallmarks of how a fast and targeted immune response can react to CNS injuries. Even 
in a resting state, microglia have been shown to be highly motile and undergo morphological 
changes, dynamically interacting with other cell types and surveilling the microenvironment 
through direct contact and their surface receptors (Nimmerjahn, 2005).  
Opposed to the non-inflammatory pathway clearing apoptotic cells, microglia utilize a second 
kind of phagocytosis to remove pathogens via toll-like receptors (TLR). Exposure to 
microorganisms, but also cytokines in a microenvironment of neuronal damage, induce a pro-
inflammatory response characterized by the upregulation of many pro-inflammatory mediators 
such as nitric oxide synthase 2 (NOS2), tumor necrosis factor alpha (TNF) or interleukins IL-
6 and IL-1β. In cell culture experiments, this is often demonstrated using lipopolysaccharide 
(LPS), a compound derived from the surface membrane of Gram-negative bacteria. A 
physiologically slightly more relevant approach using mediators such as TNFα or interferon 
gamma (IFNγ), and therefore mimicking a more sterile form of inflammation, was found to 
elicit a similar, yet less elevated inflammatory response in microglia (Lively & Schlichter, 
2018). This suggests that, as with all in vitro set ups, results should be interpreted with caution 
regarding context and relevancy. Pro-inflammatory microglia can also produce superoxides 
through NADPH oxidases (NOX). NOX2, the catalytic unit, will transfer electrons from 
nicotinamide adenine dinucleotide phosphate (NADPH) to oxygen, reducing it to superoxide 
(Lambeth, 2004). Microglia can furthermore produce nitric oxide (NO) through the inducible 




under healthy conditions is not expressed in microglia (Béchade et al., 2014, p. 2). Pioneering 
experiments showed early on how this mechanism can lead to neurotoxicity, and while NO can 
act as a signaling molecule, it is most often correlated with its anti-proliferative and pro-
apoptotic effect during the immune response (Boje & Arora, 1992; Guix et al., 2005).  
Apart from such pro-inflammatory functions, microglia can also act as neuro-protective in 
several experimental conditions. In ischemic stroke studies, microglia appear to be protective 
against induced neuronal damage (Lalancette-Hebert et al., 2007). Further investigations found 
that said neuroprotective functions are likely due to microglia engulfing invading neutrophils, 
as well as releasing the cytokine TNFα (Lambertsen et al., 2009; Neumann et al., 2008). In an 
experimental set up of spinal cord injury in rats, transplanted microglia also showed a beneficial 
effect of the growth of neuronal processes. This beneficial influence is likely due to the 
production and release of cytokines and growth factors, such as transforming growth factor 
beta (TGF-β), which is also found in the lesioned spinal cord (Rabchevsky & Streit, 1997). The 
production of TGF-β by microglia is thought to be crucial for an anti-inflammatory response 
and inducing a deletion of its receptor gene, Tgfbr2, was shown to significantly impair 
microglia homeostasis and increase the expression of multiple activation-associated markers 
(Zöller et al., 2018).  
1.2.2 Aging and neurodegeneration 
Microglia in the aging brain present with cytoplasmic abnormalities, such as de-ramification 
and fragmentation, that are thought to be a sign of a senescent phenotype and are coined 
dystrophic microglia (Streit et al., 2004). These cells seem to be activated, since expression of 
MHC II increases with age, as shown in early studies on non-human primates (Sheffield & 
Berman, 1998). Aged microglia have a slower response rate towards injury, reduced 
phagocytosis, as well as an altered production of inflammatory cytokines (Damani et al., 2011; 
Koellhoffer et al., 2017). Models of accelerated aging propose that aged microglia differ by 
having an increased expression of inflammatory genes as well as an increased activation in 
response to LPS, which is described as microglia priming as coined by Holtman et al (Holtman 
et al., 2015; Spittau, 2017). The overall shift towards a more pro-inflammatory environment in 
the aging brain leads to priming, where response to stimuli or stress are exaggerated and 
prolonged, ultimately leading to increased release of inflammatory mediators and longer 
recovery periods (Sparkman & Johnson, 2008). 
Microglia in the adult brain are not just involved in the process of aging per se but play vital 
roles in multiple neurodegenerative disorders. Phagocytosis of neurotoxic protein aggregates, 
myelin, neurons, or other cell debris is an important function of microglia. The consensus of 
multiple animal disease models and aging experiments is that the phagocytotic capabilities of 
microglia, similar to macrophages, decreases with age (Gabandé‐Rodríguez et al., 2020). In a 
meta-analysis, Holtman and colleagues described a distinct microglia phenotype hypersensitive 
to pro-inflammatory stimuli, representing primed microglia (Holtman et al., 2015). They 
specifically found a downregulation of common microglia markers such as TMEM119, 




phagocytic and antigen-presenting signaling pathways, and genes of Alzheimer’s Disease (AD) 
signaling. As aging is also the most important risk factor for neurodegenerative disorders such 
as AD, understanding the processes that microglia undergo in the aging brain may hold the key 
to developing novel therapeutic approaches for many age-related diseases (Bullain & Corrada, 
2013). 
AD is a common neurodegenerative disorder with an estimated prevalence of 6-8% in the 
population of 85 years and older (Mayeux & Stern, 2012). It is characterized by accumulation 
of amyloid-β peptides as well as hyper-phosphorylated tau forming intraneuronal fibril tangles 
(Selkoe, 2001). AD susceptibility genes are often known microglia markers such as TREM2 
(Jonsson et al., 2013) or PU.1 (Rustenhoven et al., 2018), and are associated with the 
phagocytic clearing pathway (the Alzheimer’s Disease Neuroimaging Initiative et al., 2011). 
In support of these findings, experiments have shown how early recruitment of microglia is 
initially neuroprotective, but can become pro-inflammatory and neurotoxic, at least in some 
instances, as pathological burden increases and clearance is impaired (Hickman et al., 2008; 
Krabbe et al., 2013). Especially the AD risk factor CD33 is implicated in the phagocytosis of 
amyloid-β by microglia, suggesting a significant involvement of these cells in the pathology of 
AD likely due to impaired phagocytic functions (Griciuc et al., 2013). However, an in vivo AD 
model with ablation of microglia showed no significant difference in either formation, or 
maintenance of amyloid-β pathology, raising further questions regarding their exact 
involvement in disease progression (Grathwohl et al., 2009). Synaptic loss is a hallmark of 
neurodegenerative disorders, even before the onset of pathological plaque formations. Gene 
expression analysis found elevated levels of complement 3 (C3) in aged retinal microglia, and 
it is known that C3-dependent signaling is involved in the phagocytosis and synapse loss in 
AD (Stephan et al., 2012). 
Neuroinflammation has been identified as a disease risk factor, or risk-escalating factor for AD, 
yet anti-inflammatory drugs fail to halt disease progression. Epidemiological studies have 
shown a potential effect of non-steroidal anti-inflammatory drugs on the onset of AD, however, 
the discrepancy to non-successful clinical trials may be due to the longer time periods of 
administration necessary to elicit a response (Rivers-Auty et al., 2020).  Microglia-mediated 
inflammation is typically initiated via damage-associated molecular patterns (DAMP), like 
aggregated or misfolded proteins. This can lead to chronic neuroinflammation, where aggregate 
clearance is impaired and neurotoxic factors are produced and released by microglia (Block & 
Hong, 2007). This chronic activation is subject to clinical research, for example targeting 
microglia via nanoparticles in Alzheimer’s or Parkinson’s Disease, with one nanoparticle study 
currently being in a phase I clinical trial for AD (H. Liu et al., 2020; N. Zhao et al., 2020). 
Disease-associated microglia (DAMs), a transcriptionally distinct microglial activation state in 
neurodegeneration, specifically AD, as described by Keren-Shaul and colleagues, show 
elevated expression levels for AD risk factor genes such as Apoe and Trem2 (Keren-Shaul et 
al., 2017). The latter is further orchestrating the transition of microglia in the aging brain 
towards the DAM phenotype. As shown by Kraseman and colleagues, this in turn is modulated 




DAM transcriptome and a potential target to rescue the homeostatic microglia phenotype in an 
AD mouse model (Krasemann et al., 2017). Microglia have also been shown to be implicated 
in amyloid-β as well as tau pathologies. The activation of NLRP3 via amyloid-β leads to a pro-
inflammatory and neurotoxic activation of microglia (Halle et al., 2008). This has also been 
shown to impact the pathogenesis of AD in vivo, where NLRP3 deficiency led to decreased 
deposition and overall levels of amyloid-β, and an increased microglia phagocytosis of 
amyloid-β in an APP mouse model of AD (Heneka et al., 2013). The activation of the NLRP3 
inflammasome in microglia by tau could also be shown in a mouse model for fronto-temporal 
dementia overexpressing human tau, suggesting a similar mechanism as seen in the AD model 
(Ising et al., 2019). Microglia furthermore seem to be involved in the seeding, and therefore 
propagation, of amyloid-β pathology in AD models (Venegas et al., 2017). Even though the 
past years have brought tremendous advances for the knowledge on microglia in aging and 
neurodegeneration, there is still the need to find suitable therapeutic options for not just disease 
onset, but also progression of AD and other disorders. Additionally, the limited lifespan of mice 
provides a challenge when researching aging or age-related diseases. Therefore, exploring 
novel models of microglia in aging could help understand mechanisms underlying not only 
healthy aging, but also the development of neurodegenerative diseases. 
1.2.3 Transcriptomics of activation states 
In recent years, it has been shown that microglia exhibit huge spatial and temporal 
heterogeneity, and more and more subsets of microglia throughout developmental phases are 
identified based on, e.g., their transcriptome (Li et al., 2019; Masuda et al., 2020). This vast 
heterogeneity of microglia is reflected in the number of activation states and even subtypes that 
have been identified to date. A subtype, as opposed to an activation state, describes an intrinsic 
microglia population that is found alongside canonical microglia in the CNS, without the 
impact of environmental factors, such as external inflammatory stimuli. These subtypes include 
morphologically specialized “satellite” microglia interacting with the axon initial segment to 
support homeostasis in the healthy brain, KSPG-microglia which appear to be insult-related, 
or CD11c-microglia promoting neurogenesis and myelination (Baalman et al., 2015; Bertolotto 
et al., 1993; Wlodarczyk et al., 2017). 
Some activation patterns may indeed reflect certain subtypes; however, this remains to be 
proven. One aspect of said heterogeneity is the difference in features based on the CNS region 
the microglia are found in. Some examples, as reviewed extensively, have different 
morphologies, densities, and expression of markers such as CX3CR1, TREM2 or immune-
related genes (Y.-L. Tan et al., 2020). It is mostly unclear yet if and how these regional 
differences can impact the functional signatures of microglia. One study approached this 
question with a genome-wide analysis of microglia from distinct regions, as well as comparing 
young versus aged animals. The extracted cells showed regionally heterogeneous 
transcriptomes, suggesting different immune-vigilant states depending on the distinct brain 




More recent advances in bulk and single cell RNA sequencing (scRNA-seq) methods have 
made their contributions to the field by elucidating the transcriptomic profiles of activated or 
disease-associated phenotypes. In the human brain, scRNA-seq identified region- and age-
dependent microglia clusters, demonstrating high heterogeneity of transcriptome signatures 
(Sankowski et al., 2019). Throughout development, the highest heterogeneity as analyzed in 
mice seems to occur during early development, and even certain microglial marker genes such 
as P2ry12, Tmem119 or Cx3cr1 show altered expression levels during developmental stages 
(Hammond et al., 2019). The same study also identified microglia clusters with upregulated 
inflammatory response genes in the aged mouse brain, which may contribute to the onset or 
progression of age-related disorders (Hammond et al., 2019).  
In aged human microglia, RNA-seq analysis resulted in a distinct transcriptomic profile 
including susceptibility genes associated with AD (Olah et al., 2018). The same study 
furthermore showed that the transcriptome of aging microglia was associated with a gain of 
function for genes in the amyloid fiber formation pathway, suggesting that certain, but not all 
neurodegenerative disorders might be mediated through aged microglia. Interestingly, 
microglia that were Cx3cr1-deficient, which is usually a highly expressed microglia marker, 
presented with a transcriptome and morphology similar to that of aged microglia, suggesting 
that the receptor protein is involved in regulating microglia aging (Gyoneva et al., 2019). A 
comparison between aged human and aged mouse microglia found little overlap of their 
transcriptomes, indicating a difference in how these cells age between species even though the 
core signature at steady-state was found to be similar (Galatro et al., 2017; Gosselin et al., 
2017). Through scRNA-seq, Keren-Shaul and colleagues found that DAMs are enriched for 
genes that are known risk factors for AD or are involved in phagocytic pathways, and that their 
activation is orchestrated by TREM2 (Keren-Shaul et al., 2017). On the other hand, studies 
performed on human post-mortem tissue failed to identify subsets with DAM signature genes 
in AD brain samples (Alsema et al., 2020). More recently, studies in zebrafish identified two 
additional microglia subpopulations, synaptic region-associated microglia (SAM) and 
neurogenic-associated microglia (NAM) (Silva et al., 2021). These activation states show 
transcriptionally distinct profiles regarding the brain region, as well as their function, with 
SAMs locating predominantly in the synapse-rich hindbrain where they engulf synapses as a 







Figure 1: Microglia can acquire different phenotypes depending on their environment or 
activating stimulus. (A) Surveying microglia fulfill roles throughout development as well as in 
the healthy adult brain, ranging from regulating neuronal precursor cells to pruning synapses, 




markers include TMEM119- and P2RY12-positivity, expression of transcription factor SALL1 
or a high expression of CX3CR1 (Bennett et al., 2016; Buttgereit et al., 2016; Jurga et al., 
2020). (B) In a highly simplified model, microglia are often classified as classically or 
alternatively activated, speaking of pro- or anti-inflammatory phenotypes. Anti-inflammatory 
phenotypes will show upregulated markers such as ARG1, IL-10 or TGF-β and are involved in 
tasks like repair after traumatic injury and neurogenesis (Cherry et al., 2014). Pro-
inflammatory phenotypes on the other hand are involved in stress- and inflammatory-mediated 
reactions and produce cytokines IL-1β, IL-6 and TNF-α, as well as nitric oxide (J. A. Smith et 
al., 2012). (C) Depending on physical microenvironment, age, or disease occurrence, 
microglia will acquire distinct morphological and transcriptomic signatures. Some examples 
shown here include neurogenic associated microglia (NAM), synaptic-region associated 
microglia (SAM), tumor-associated microglia (TAM), disease-associated microglia (DAM), or 
microglia primed through the normal aging process (Hammond et al., 2019; Keren-Shaul et 
al., 2017; Sa et al., 2020; Silva et al., 2021). 
 
As presented in these large number of studies, sequencing techniques can be used to identify 
manifold microglia states or possible microglia subtypes based on their transcriptomic profiles 
extending far beyond the traditionally labeled pro- or anti-inflammatory states (Figure 1). 
However, a caveat of most current advances using single cell sequencing is that the actual 
functions of these identified subsets of microglia still need to be elucidated to draw more 
relevant conclusions. Methodologically, there is also variation in the analysis of sequencing 
data such as different available clustering methods, introducing challenges when comparing 
data. Additional discussion points are the comparison between human and mouse microglia, as 
well as in vivo versus in vitro transcriptomes. In a study by Gosselin and colleagues, a well-
conserved transcriptomic signature was found between human and mouse cells, although 
certain genes involved in the development of brain structure or the complement pathway were 
distinctly different between the species (Gosselin et al., 2017). Changes were also observed in 
vitro compared to ex vivo, especially in genes associated with an acute inflammatory response, 
likely due to the loss of signals from the brain environment. It is now abundantly clear that 
microglia are highly plastic cells with the ability to respond to a great deal of stimuli with a 
wide range of adaptable cellular functions. This remarkable ability for a single cell type begs 
the question of how these phenotypes can be regulated and how they can be differentiated, 
however, caveats in possible differences due to methods used, species analyzed, or the cells’ 






1.3 Microglia regulation 
1.3.1 Transcription factors associated with microglia homeostasis or 
activation 
Microglia and their activation states can be regulated by a number of pathways and 
transcription factors, depending on the activating stimulus. Analysis of the binding sites and 
regulatory elements of genes of interest expressed in activated microglia states has given 
insight into how these phenotypes may be regulated. Nuclear factor κB (NF-κB) signaling is 
of particular importance to the regulation of immune cell responses and the initiation of 
inflammation (T. Liu et al., 2017). It represents a family of transcription factors including p65 
(or RelA), p50 (NF-κB1), p52 (NF-κB2), c-Rel and RelB (Verma et al., 1995). Upon activation 
and dimerization in homo- or heterodimers, the subunits translocate into the nucleus where they 
bind DNA at recognized κB binding sites. As reviewed comprehensively elsewhere, the lists 
of inducers for NF-κB are extensive and include exposure to viral or bacterial infection, 
oxidative stress, environmental stress, or different receptor ligands. Similarly, there are 
hundreds of target genes, often such that are required for immune response and cell survival 
(Pahl, 1999). In macrophages, NF-κB signaling is known to be crucial for the polarization of 
these cells mostly towards a pro-inflammatory phenotype. Through receptors such as TLR4, 
which recognizes LPS as a ligand, and the sequential activation of kinases downstream of 
TLR4, NF-κB induces genes necessary for the inflammatory response (T. Liu et al., 2017). The 
pathway is furthermore activated by the presence of α-synuclein or amyloid-β, where it 
promotes a pro-inflammatory cascade contributing to the pathogenic involvement of microglia 
in neurodegenerative disorders (Chen et al., 2005, p. 1; Hoenen et al., 2016). LPS-induced 
signaling mediated through TLR4 can also act via mitogen-activated protein kinase (MAPK) 
pathways, leading to the activation of the transcription factor family of activator protein 1 (AP-
1) (W. Liu et al., 2009). In macrophages and dendritic mouse cells, pro-inflammatory 
expression of cytokines such as IL-23 have been shown to involve NF-κB as well as AP-1, and 
the interaction of these transcription factors in the regulation of pro-inflammatory responses 
has also been shown in microglia (Jeong et al., 2020; W. Liu et al., 2009).  
Another transcription factor of interest is PU.1, which is found in functional macrophages and 
is constitutively expressed in quiescent and activated rodent (Walton et al., 2000), as well as 
human microglia (A. M. Smith et al., 2013). PU.1 has been shown to be important in microglia 
activation regulating gene expression. Specifically, PU.1 expression seems to spike after 
hypoxic-ischemic insults, suggesting its involvement in immune activation (Walton et al., 
2000). It is also known that PU.1 is involved in the regulation of microglial genes associated 
with AD (Rustenhoven et al., 2018). With PU.1 being a genetic risk for AD itself, interesting 
research has emerged pinpointing how PU.1 is not only regulating pro-inflammatory gene 
expression, but is also crucial for the cells’ phagocytic ability (Pimenova et al., 2021). PU.1 
has been found to be regulated via a positive feedback loop with the transcription factor 
interferon regulatory factor 8 (IRF8) (N. Zhou et al., 2019). The latter in turn is known to 




microglial motility-related genes or the activation of microglia specifically in the context of 
injury-induced neurodegeneration (Masuda et al., 2012, 2014; Minten et al., 2012). 
1.3.2 Epigenetic regulation 
Lastly, epigenetic mechanisms can impact microglia plasticity and their functions in 
homeostasis or even CNS disorders (Cheray & Joseph, 2018). Epigenetics refers to changes 
altering the physical structure of DNA, and subsequently impacting gene expression by 
increasing or decreasing DNA accessibility. This includes histone modifications, DNA 
methylation and even non-coding RNA. Such epigenetic changes can depend on a number of 
factors ranging from age, to exposure to toxins or infection, and even prenatal exposure to 
nutritional starvation (Chandran et al., 2015; Heijmans et al., 2008; Heyn et al., 2012; 
McCartney et al., 2018). 
Histones, around which DNA is tightly coiled to form packaging units known as nucleosomes, 
are subject to post-translational modifications – acetylation, methylation, or phosphorylation 
of the histone tails are the most common and can result in direct structural changes or impact 
the DNA binding of other proteins (Bannister & Kouzarides, 2011). Histone acetylation is 
mediated by two types of enzymes, histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). In microglia, a switch towards the glioma-induced pro-tumoral phenotype was 
correlated to increased H4K16 acetylation mediated by the HDAC sirtuin 1 (SIRT1) and the 
HAT hMOF, resulting in increased expression of genes associated with a tumor-supporting 
microglial phenotype (Saidi et al., 2018). The epigenetic regulation of lineage-determining 
transcription factors such as PU.1 or SALL1 can therefore determine the DNA accessibility 
and expression of microglia signature genes. Increased acetylation of histone H4 at the PU.1 
promotor region, for example, leads to decreased PU.1 expression, mediated via the inhibition 
of HDACs (Laribee & Klemsz, 2005). The pharmacological inhibition or genetic targeting of 
HDACs has also been tested after spinal cord injury and in LPS-activated mouse microglia, 
leading to a decreased inflammatory response (Alireza Abdanipour et al., 1996; Kannan et al., 
2013).  
Histone methylation of H3K27 as well as of H3K4 have been shown to be in positive 
correlation with microglia activation. The inhibition of the enhancer of zeste homolog 2 
(EZH2) histone-methyltransferase within the polycomb repressive complex 2 (PRC2) 
modulates the transcription factors IRF8 and STAT1, which are implicated in the expression 
of inflammatory-related genes (Arifuzzaman et al., 2017). H3K27me3, and PRC2, were also 
associated with the repression of genes related to clearance activity in mice, impacting neuronal 
morphology and function (Ayata et al., 2018). Furthermore, H3K4 methylation was associated 
with DAM-specific microglial genes marking promotor and enhancer regions (Keren-Shaul et 
al., 2017). In an effort to elucidate how amyloid-β accumulation may impact microglia 
transcriptomic changes via epigenetics, Wendeln and colleagues found increased levels of 
H3K4me1 in mouse microglia after pro-inflammatory stimulation with LPS, as well as in 
APP23 mice, a model for AD (Wendeln et al., 2018). This particularly affected genes involved 




metabolism, mitochondrial respiration and response to hypoxic conditions as can be observed 
in the AD brain (Ashok et al., 2017).  
1.3.3 Autophagy in microglia 
Autophagy, or components of the autophagic pathway, are also gaining interest as potential 
regulators of microglia and overall processes in the CNS such as aging, neurodegenerative 
diseases or epilepsy models (Alam et al., 2021; Plaza-Zabala et al., 2017; Su et al., 2016). 
Derived from the Greek words for ”self” (auto) and ”eating” (phag-), autophagy is primarily 
the selective bulk degradation of proteins and organelles to maintain cellular homeostasis and 
can be induced by a multitude of stimuli, such as amino acid- and nitrogen-starvation, ER-
stress, hypoxia, as well as other stress-related pathways  (Ecker et al., 2010; Mazure & 
Pouysségur, 2010; Onodera & Ohsumi, 2005; Rashid et al., 2015). In general, one can 
differentiate between three main types of autophagy. During micro-autophagy, cytosolic 
components are, usually non-selectively, internalized directly into lysosomes. (Parzych & 
Klionsky, 2014). Chaperone-mediated autophagy uses the recognition of specific amino acid 
motif sequences of substrate proteins. The substrate is bound and translocated by so-called 
chaperone proteins to a lysosome for degradation, hence the name of the process (Cuervo & 
Wong, 2014). Macro-autophagy on the other hand utilizes double-membrane vesicles, formed 
de novo around components to be degraded, followed by fusion with enzyme-carrying 
lysosomes. There is furthermore a selective, organelle-specific type of macro-autophagy which 
aims to remove damaged components of the cells, such as mitophagy for degrading 
mitochondria (Swerdlow & Wilkins, 2020). In the following text, the term autophagy will 
however simply refer to the process of macro-autophagy. 
The process of autophagy is mediated by a number of autophagy-related genes and proteins 
and is characterized as sequential formation of double-membrane vesicles engulfing cargo to 
be degraded. In an initial step of induction and nucleation, the phagophore expands and forms 
the autophagosome by closing into a vesicle. In mammals, this step is mainly controlled by the 
interaction of ATG4 and MAP1LC3 (microtubule associated protein 1 light-chain 3, hereafter 
referred to as LC3) (Xie et al., 2008, p. 8; Y. Zhou et al., 2021). LC3 is cleaved and sequentially 
conjugated to phosphatidylethanolamine (PE), which creates the membrane-bound LC3-II. 
This step is coordinated through the activation of, sequentially, ATG7, ATG3, and the 
ATG12/ATG5/ATG16L1-complex, acting as E1-like, E2-like and E3-like enzymes, 
respectively (Y.-K. Lee & Lee, 2016). ATG7, similar to ATG10, also plays the role of an 
activating E1-like enzyme in the conjugation of ATG12 with ATG5, before they then associate 
to ATG16L1 to form this complex (Walczak & Martens, 2013). These key aspects make ATG7 
an interesting target when studying autophagy. After the autophagosome fuses with a lysosome 
carrying enzymes such as hydrolases, the vesicle becomes an autolysosome. Following the 
enzymatic degradation of the vesicle cargo into molecules like amino acids, autophagy-related 
proteins such as ATG22 are involved in the release of the molecules back into the cytosol 
(Yang et al., 2006). The steps of autophagy as described above, and the roles of ATG7 





Figure 2: Simplified schematic of the autophagy process. Different stimuli, such as nutrient 
starvation or other stressors, initiate autophagy. During the first step, the double-lipid 
membrane starts to form to incapsulate the cargo. The elongation of the phagophore is 
finalized in the autophagosome, which then fuses with enzyme-carrying lysosomes. The then 
formed autolysosome degrades its cargo into molecules and releases these to be used in 
anabolic synthesis of, e.g., proteins or cell components. ATG7 plays an important role during 
autophagy in mainly two functions. First, it acts as an E1-like enzyme in the conjugation 
process of ATG12 and ATG5, which then form a complex together with ATG16L1. ATG7 
furthermore activates and facilitates the transfer of LC3 to ATG3. The E3-like enzyme complex 
of ATG12/ATG5/ATG16L1 then localizes to the expanding membrane of the phagophore to 
facilitate the conjugation of LC3 with PE. 
 
Autophagy-related proteins can exhibit roles outside of their function in the autophagy process. 




implicated in the release of viral particles via exocytosis, as well as in inflammation-associated 
endocytosis (Münz, 2021). In murine macrophages, ATG16L1 was linked to the control of the 
endotoxin-associated inflammatory immune response by regulating the inflammasome 
activation (Saitoh et al., 2008). An additional implication in the immune response is that ATG5 
regulated MyD88-dependent signaling, which is an adaptor protein for TLRs and therefore 
crucial for the signaling cascades following TLR stimulation (Inomata et al., 2013). ATG7 as 
well as the complex ATG12/ATG5/ATG16L1 are required for the IFNγ-mediated antiviral 
host defense in mouse macrophages, where the activation of IFNγ was dependent on the 
complex without the induction of autophagy itself (Hwang et al., 2012). ATG7-deficiency is 
also linked to an accumulation of p62, and the interplay of p62 and NF-κB forms an intrinsic 
feedback loop regulating inflammatory responses (Zhong et al., 2016). Specifically in 
microglia, ATG7-deficiency has been shown to disrupt the clearance of tissue debris or 
amyloid-β fibrils in mouse disease models such as for multiple sclerosis or AD, exacerbating 
neuroinflammation (Berglund et al., 2020; Cho et al., 2014). ATG7 has also been implicated 
in transcriptional regulation, which makes it an interesting target to research regarding the 
activation of certain cell types, such as microglia. One example in nutrient-deprived mouse 
fibroblasts showed that ATG7 could bind the transcription factor p53 and therefore regulate 
the transcription of genes implicated in cell cycle arrest (I. H. Lee et al., 2012). Conversely, the 
study found induced expression of pro-apoptotic genes mediated by p53 in Atg7-deficient cells. 
ATG7 was also found to bind to the transcription factor FOXO1, which is implicated in 
induction of autophagy itself and autophagic cell death (Y. Zhao, Yang, et al., 2010).  
In summary, the activation of microglia phenotypes is regulated by a vast number of factors, 
ranging from signature transcription factors to epigenetic modulations, and potentially even 








1.4 High-grade glioma 
Malignancies of the brain are amongst the most severe and difficult to treat diseases occurring 
in adults as well as in children. In a statistical report from the Central Brain Tumor Registry of 
the United States (CBTRUS) it was shown that primary brain and CNS tumors are the most 
common cancer type in children under 15 years of age, and the third most common cancer type 
in adults under 40 years (Ostrom et al., 2019). The same report stated that, of the malignant 
CNS tumors, gliomas make up over 80% of this category and glioblastomas are the most 
common subtype of malignant CNS tumor. 
Historically, CNS tumors were classified on the consensus of histopathological opinions. In 
order to implement internationally accepted standards of diagnosis, the international agency of 
research on cancer (IARC) and its group for the classification of tumors at the world health 
organization (WHO) publishes a series of guides based on pathological features and associated 
genetic alterations. These WHO Classification of Tumors are currently in their 5th edition for 
most tumor groups. The classification for CNS tumors is currently available as a revised 4th 
edition of the 2016 report, however, a summary of major changes in the 5th edition is also 
available as a separate publication (Louis et al., 2016, 2021). A summary of selected tumor 
types discussed in this thesis, namely with key diagnostic genes being IDH1, IDH2, or 
alterations in histone modification on H3, is shown in table 1. Astrocytomas (IDH-mutant) do 
now include glioblastoma IDH-mutant tumors and range in their WHO grading from grade 2 
to 4. While grade 1 and grade 2 are characterized as low-grade with slow growth and limited 
infiltration, grade 3 is classified as malignant and infiltrative, sometimes anaplastic, and grade 
4 tumors are described as having aggressive and infiltrative growth, with often rapid recurrence 
and being prone to necrosis (Louis et al., 2007). Specific pediatric brain stem tumors, 
previously termed diffuse intrinsic pontine gliomas (DIPG), are now included in the group of 
diffuse midline gliomas. They are furthermore specified as H3K27-altered, as mutations 
affecting the histone modification status are recognized as classification criteria for these 
tumors. Furthermore, H3-wildtype and IDH-wildtype diffuse pediatric-type high-grade 
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Table 1: Selected tumor classifications relevant to this thesis, and their current nomenclature 
based on a summary of the 2021 WHO Classification of Tumors of the Central Nervous System 
(Louis et al., 2021). 
 
1.4.1 Pediatric glioma 
In pediatric diffuse high-grade gliomas, variations in the genes encoding for histone H3 are of 
importance to classify and stage the tumor types. One common mutation resulting in the 
substitution of lysine to methionine (H3K27M) has been shown to be an important prognostic 
marker for worse survival compared to wildtype tumors (Khuong-Quang et al., 2012). The 
mutation leads to a global reduction of the methylated histone mark, H3K27me3, and alters 
gene expression profiles in combination with DNA hypomethylation (Bender et al., 2013). The 
same study, as well as others, additionally found that certain gene loci also show increased 
local methylation such as on the loci for cyclin dependent kinase inhibitor 2A (CDKN2A), 
leading to a complex altered program of transcriptional activation and repression at different 
loci, which may ultimately drive tumorigenesis (Chan et al., 2013). Part of this interplay in 
H3K27 mutant tumors is the increased recruitment of the PRC2 to H3K27me3 and enzymatic 




EZH2, the histone-methyltransferase of PRC2, is increased in H3K27 mutant gliomas, and was 
therefore considered a promising target for this highly aggressive pediatric cancer. Studies have 
tested small-molecule inhibitors for EZH2 with contradicting results in vivo and in vitro 
(Mohammad et al., 2017; Wiese et al., 2016). This suggests that targeting the TME and 
associated cell types may play an important role in tumor progression and the search for viable 
targets in clinical research.  
1.4.2 IDH-mutant glioma 
IDH1 and 2, or isocitrate dehydrogenase type 1 and 2, are single-gene enzymes and located in 
the cytoplasm and mitochondria, respectively. They have similar functions, providing a cell 
with NADPH catalyzed from the co factor NADP+. The reduced form, NADPH, is a crucial 
electron donor in numerous anabolic reactions and implicated in the genesis and progression 
of different cancer types, whereas it can likely impact metabolism and oxidative stress (Ju et 
al., 2020). Mutations in IDH2 are much less frequently found in gliomas and seem to be 
mutually exclusive with mutations in IDH1 (Cohen et al., 2013). A commonly found missense 
mutation affecting amino acid residue 132 (R132H) on IDH1, replacing the arginine residue 
with histidine, has been shown to lead to neo-enzymatic activities of mutant IDH1. 
Dramatically elevated levels of 2-hydroxyglutarate (2HG) in glioma as a result of this gain-of-
function mutation have been linked to epigenetic changes. 2HG can act as an inhibitor for 
histone and DNA demethylases, and therefore cause an increase in their methylation levels. 
This in turn is hypothesized to inhibit the binding of certain transcription factors, leading to 
altered gene expression and potentially cancer progression (Raineri & Mellor, 2018). It is 
therefore somewhat surprising that the mutation status of IDH1 in grade 2 to 4 gliomas is an 
important, independent and favorable prognostic biomarker (Sanson et al., 2009). In lower 
grade gliomas, a significant correlation between IDH1-mutation and hypermethylation of the 
promotor for the O6-methylguanine-DNA methyltransferase (MGMT) has been found, leading 
to favorable overall survival due to higher sensitivity to certain therapeutic agents (Pandith et 
al., 2021). This suggests a more extensive and complicated epigenetic landscape in these 
tumors that needs to be further explored. 
1.4.3 Microglia and macrophages in the TME 
A different angle of research studies indicates that immune cells in the TME play a role in 
oncogenesis, progression, diagnosis, and treatment. For example, in IDH-wildtype 
glioblastoma, which present with a less favorable disease progression, significantly more 
glioblastoma-associated microglia and macrophages are found compared to the mutant tumor 
(Poon et al., 2019). Tumor-initiating cells can recruit microglia to the tumor site, where 
microglia in turn will upregulate the release of IL-6 benefiting the tumor growth by supporting 
glioma stem cells (a Dzaye et al., 2016). Recruitment of microglia, but also infiltrating 
macrophages, is mediated by the release of chemo-attractants such as C–C motif ligand 2 
(CCL2), C-X-C motif chemokine 12 (CXCL12),  glial cell–derived neurotrophic factor 
(GDNF), or granulocyte-macrophage colony-stimulating factor (GM-CSF) (Hambardzumyan 




glioma-associated microglia and macrophages (GAM) have been reported to promote glioma 
growth and invasion by releasing growth factors. Glioma invasion and migration are aided by 
intricate signaling initiated by the secretion of microglial TGF-β, which involves a cascade of 
matrix metalloproteinases to modulate the extracellular matrix, and can be enhanced further by 
microglia-activating factors such as GM-CSF (Bettinger et al., 2002; Wick et al., 2001). TGF-
β, which is produced by glioma cells as well as TAMs, can furthermore inhibit T lymphocyte-
mediated tumor cytotoxicity by suppressing gene expression and ultimately hindering tumor 
clearance (Thomas & Massagué, 2005). Hypoxia further increases the recruitment and 
polarization of macrophages towards glioma, and immunosuppressive hypoxic effects such as 
upregulation of TAM-expressed macrophage colony-stimulating factor receptor (M-CSFR) or 
glioma-expressed TGF-β are regulated by transcription factors STAT3 and HIF (Guo et al., 
2016; Wei et al., 2011). In a preclinical study, STAT3 inhibition showed limited activity which 
was partly due to molecular heterogeneity of glioblastoma, and additional challenges such as 
low penetration rates of the blood-brain barrier (M. S. Y. Tan et al., 2019). The above-described 
events can be summarized as escaping the immune surveillance and creating an immune-
suppressive TME. Clinical trials for immune therapies such as checkpoint inhibitors show 
promising results in other cancers, but have unfortunately not yet been successful in 
glioblastoma trials (Reardon et al., 2020). Other therapeutic approaches such as utilizing 
chimeric antigen receptor (CAR) T cell therapies in pediatric high-grade glioma (pHGG) also 
remain to show efficiency, and limitations include the immune-suppressive TAM 
microenvironment as well as penetration rates and persistence of the CAR T cells (Haydar et 
al., 2021). 
Immune cells in the glioma microenvironment have been targeted by several studies aiming to 
find successful treatment approaches, with most approaches following strategies to inhibit the 
recruitment of TAMs, depleting TAMs or reprogramming TAMs (Zhang et al., 2020). For 
example, inhibition of CXCR4, the receptor for CXCL12, led to decreased immune cell 
infiltration post-radiation in mice, impacting vasculogenesis of the tumor (Kioi et al., 2010). A 
different approach aims to target the immune evasion of glioma cells via the upregulation of 
the anti-phagocytic cell surface protein CD47. In the TME, CD47 is recognized by the receptor 
signal regulatory protein SIRPα expressed on microglia and macrophages, leading to a “don’t 
eat me” signaling cascade. In xenograft models of pediatric brain tumors, such as pediatric 
glioblastoma, the use of an anti-CD47 antibody disrupted anti-phagocytic signaling in 
macrophages, and CD47 blockade in glioblastoma models showed enhanced tumor 
phagocytosis by microglia (Gholamin et al., 2017; Hutter et al., 2019). Inhibiting CSF-1R 
seems to show beneficial effects on glioma progression and proliferation by modulating and 
targeting the immuno-suppressive activation of the TAMs, strengthening the hypotheses of the 
TME playing a crucial role in finding novel treatment strategies (Yan et al., 2017). CSF-1R 
inhibition in preclinical glioblastoma mouse studies resulted in increased tumor sensitivity to 
irradiation and depletion of CD11b+ cells (Stafford et al., 2016). However, other studies found 




need for further investing contributing pathways and potential combination treatments to 
combat resistances (Quail et al., 2016).   
A challenge presented to researchers is how to properly distinguish tumor-associated microglia 
from infiltrating macrophages, especially considering that their transcriptomic signatures will 
change once recruited to the tumor site (Klemm et al., 2020). Apart from full sets of genetic 
signature genes differentially expressed in microglia versus macrophages, reports suggest 
CD49d as a distinguishing marker in human and mouse samples that is stable at both steady 
state and during activation, see also figure 3 (Bowman et al., 2016; Haage et al., 2019). 
TMEM119 and P2RY12 were also found to be robust markers to distinguish microglia from 
macrophages, whereas other markers were upregulated in tumor-associated microglia and not 
just found in macrophages (Woolf et al., 2021). 
 
Figure 3: Interaction between glioma cells, resident- and infiltrating immune cells in the TME. 
To recruit microglia or infiltrating macrophages, glioma cells will secrete factors such as 
CCL2, CXCL12, GDNF or GM-CSF. TAMs in turn release cytokines and growth factors 
supporting the tumor growth and invasion and decrease their phagocytic activity. The interplay 
of tumor-associated microglia with macrophages is yet to be fully understood. Markers to 
distinguish the two cell types to investigate their distinct functions in models include CD45 and 
CD49d. 
 
Relatively little is known about the underlying differences of microglia versus infiltrating 
macrophages within the TME, or the transcriptomic differences of TAMs between different 
types of gliomas. In an effort to compare TAMs between DIPG and adult glioblastoma samples, 
RNA-seq on human samples revealed that DIPG-associated TAMs show a significantly less 
inflammatory phenotype, emphasizing the need for targeted strategies depending on tumor and 
TME heterogeneity (Lin et al., 2018). In glioma mouse models, TAM microglia showed 
distinct transcriptomic activation compared to TAM macrophages (Bowman et al., 2016). 
There, Bowman et al. found enrichment of immune effector genes as well as some genes 
associated with immune suppression in TAM macrophages, while TAM microglia showed 




microglia as well as infiltrating macrophages could even be differentiated between IDH 
wildtype and IDH mutant glioblastoma, and signature gene expression profiles influenced by 
the underlying type of tumor could even be used as a predictive marker for disease outcome 
(Klemm et al., 2020). In a recent study, a higher ratio of microglia in TAMs in glioblastoma 
was found to be beneficial for survival, affirming the need to analyze these cell populations 
individually (Woolf et al., 2021). 
Targeting TAMs in the context of glioma presents to be promising for therapeutic 
interventions, however, the distinct roles of microglia and recruited macrophages need to be 
better understood in order to achieve higher target specificity and a more personalized approach 
based on the underlying tumor type and composition of TME. Since macrophages acquire a 
distinct transcriptomics profile compared to microglia in the context of glioma, and the number 
of infiltrating macrophages versus resident microglia can be associated with disease 
progression, it is furthermore of interest to elucidate the possible interactions between these 
immune cells in the TME. 
To briefly summarize: understanding the transcriptomic signatures and associated functional 
activation states or subtypes of microglia could help answer a wide range of research questions. 
Insights into how these specialized immune cells adapt throughout development and aging, 
how they become dysfunctional in neurodegeneration and how they impact the composition 
and cell communication within the TME could enable us to harvest that potential by modulating 
or reprogramming them. We should furthermore aim to understand the regulation and pathways 
involved explaining differences depending on the spatial-, time-, stimuli- or disease-dependent 





2 RESEARCH AIMS 
Overall, this thesis aims to increase knowledge and support the gain of insights into microglial 
activation and regulation. The projects presented as published papers or manuscripts are 
focused on individual aspects of microglia phenotypes in the context of inflammation, the TME 
including tumor-associated microglia and macrophages, and the aging brain. The research aims 
are specified as follows: 
 
Paper I – Atg7 deficiency in microglia drives an altered transcriptomic profile associated 
with an impaired neuroinflammatory response 
Distinct profiles of gene expression have been reported in microglia activated towards certain 
phenotypes. Using stimuli such as LPS, we provoked a pro-inflammatory response and 
characterized their transcriptome and altered functions. Remarkably, Atg7-deficient microglia 
showed diminished activation on a transcriptional, as well as on a functional level. To elucidate 
the mechanisms behind such altered transcriptomic signatures, we aim to identify a relevant 
modulator of microglial activation selectively towards an inflammatory phenotype.  
 
Paper II/Manuscript – Aged microglia: development of immunosenescence without 
replicative senescence 
Microglia present altered transcriptomic profiles and functional phenotypes in the healthy 
aging brain as well as in the context of neurodegenerative disorders. Cellular senescence is 
characterized by mitochondrial dysfunction, senescence-associated secretion of pro-
inflammatory cytokines or metabolic imbalances leading to protein aggregates, which likely 
contributes to the overall process of the aging brain. In this study, we aim to model cellular 
aging with a long-term cultivation of microglia and perform functional cell assays, as well as 
transcriptomic analyses.  
 
Paper III – Inhibition of microglial EZH2 leads to anti-tumoral effects in pediatric diffuse 
midline gliomas 
Pediatric diffuse midline gliomas are known to be aggressive tumors of the brain stem with a 
significant lack of treatment options. In this study, we aim to understand the effect of EZH2 
inhibition on the tumor-associated microglia, leading to an anti-tumoral phenotype. We 
furthermore wanted to characterize an epigenetic mechanism behind the tumor-induced 
activation of microglia, elucidating their impact on the TME and their potential use as future 




Paper IV/Manuscript – Understanding if the presence of peripheral macrophages in the 
context of glioblastoma influences the tumor-associated microglial phenotype 
Tumor-associated microglia and macrophages are often described and researched as a group of 
cells with significant impact on the TME. In this project however, we aim to specifically 
elucidate the individual contributions of microglia and infiltrating macrophages in the 
glioblastoma context, hypothesizing that an initial anti-tumoral microglia phenotype can be 




3 MATERIALS AND METHODS 
Cell Lines: The studies presented in this thesis make use of a variety of established cell lines 
from mouse, rat, or human origin. In vitro approaches provide a good basis for investigating 
molecular mechanisms in an initial and simplified form, without the need of laboratory animals. 
However, cell culture also poses challenges such as lack of other cell types usually present in 
the microenvironment, or potential differences in gene expression between primary cells and 
established cell lines. With awareness of the in vitro downsides, we have opted to use functional 
assays, reproducing findings in multiple cell lines, using primary patient-derived cell lines, or 
utilizing human tissues through external collaborations to validate our findings. The following 
cell models were used: 
BV2 microglia: they are of a murine, C57BL/6J background and immortalized using a -raf/v-
myc oncogene carrying retrovirus (Blasi et al., 1990). These cells have been found to be a 
suitable model compared to primary cells and show similar, even though less pronounced, 
reaction to inflammatory stimuli (Henn, 2009).   
To study the impact of Atg7, we received shControl and shAtg7 BV2 as a generous gift from 
Dr. Seong-Woon Yu, Daegu Gyeongbuk Institute of Science and Technology, Republic of 
Korea. The cells were generated using lentiviruses (J.-W. Lee et al., 2019). 
HMC3 microglia: HMC3 are human fetal brain-derived primary microglia cells, immortalized 
using simian virus 40 (Janabi et al., 1995). These cells were obtained from ATCC (CRL-3304) 
and used to validate findings from rodent cell lines in human-derived cells.  
RAW 264.7 macrophages: this murine macrophage cell line was generated using Abelson 
murine leukemia virus-transformed cells from a BALB/c mouse strain (Raschke et al., 1978). 
The cells were obtained from ATCC (TIB-71). 
MN9D neurons: cells were a kind gift from Dr. Alfred Heller, University of Chicago, USA. 
These cells represent dopaminergic neurons and were generated by somatic cell fusion using a 
14-day-old embryonic C57BL/6J mouse (Choi et al., 1991). Neuronal cells were used for a 
functional assay investigating induced neurotoxicity. 
C6 glioma: Cells were obtained from ATCC (CCL-107) and are a rat glioma cell line that was 
first induced using N-nitrosomethylurea (Benda et al., 1968). This cell line was chosen for 
functional assays as it can overall simulate glioblastoma multiforme as a good model 
(Giakoumettis et al., 2018). 
SF188 glioblastoma: This human pHGG cell line was used as a control line to SF8628. The 
line is primary patient-derived and was a kind gift from Stefan M. Pfister, German Cancer 
Research Center. 
SF8628 glioma: This DIPG cell line carries a substitution mutation on histone H3.3 (lysine 27 





U87 glioblastoma: Human cell line of male origin, likely derived from malignant glioblastoma 
patient tissues (Pontén & Macintyre, 2009). Allen et al. showed a different DNA profile of 
currently distributed cells from ATCC compared to the original cells, likely to be glioblastoma 
of unknown origin (Allen et al., 2016). Our cells were obtained from a stock from B. 
Westermark originator's laboratory, Uppsala University, however, this information demands 
caution when comparing literature using this cell line. Apart from this wildtype U87MG cell 
line, we also studied the effect of the commonly reported IDH1 mutation. Therefore, we used 
a human glioma cell line with knock-in IDH1 mutation (IDH1R132H), generated using 
CRISPR/Cas9 gene editing technology (ATCC, HTB-14IG).  
U251 glioblastoma: This cell line was originally derived from a male patient with malignant 
astrocytoma, presented in the same study as the original U87MG cells (Pontén & Macintyre, 
2009). The cells used in this thesis were obtained from the same laboratory (B. Westermark) 
as the U87 cell line. 
U1242 glioblastoma: This cell line originated from a malignant human glioma of  (Lubitz et 
al., 1980) and was chosen for the analysis of a highly aggressive and invasive tumor compared 
to U87MG, as shown by xenograft invasion experiments (Y. Zhao, Xiao, et al., 2010). We 
obtained our cells from the same laboratory (B. Westermark) as the U87 and U251 cell lines. 
Immunoblotting: Protein analysis using the Western blot method allowed to study the 
presence, molecular size, and quantity of specific proteins present in the cell samples. In brief, 
cell lysates were collected, sonicated, and boiled, before separated by gel electrophoresis in 
SDS–polyacrylamide gels with appropriate percentages. Subcellular fractionation, instead of 
whole cell lysates, was used for some experiments to show the distribution of proteins in the 
cytoplasm compared to the nucleus. After blocking and incubating with the indicated 
antibodies, membranes were imaged using the LI-COR Biosciences Odyssey CLx infrared 
imaging system and images were quantified using ImageJ software. 
Immunohistochemistry: Immunohistochemistry (IHC) was performed to visualize the 
location and amount of specifically labeled proteins in cells, using confocal microscopy. Cells 
seeded on glass coverslips were fixed with paraformaldehyde solution, incubated with blocking 
solution and afterwards with the indicated antibodies and DNA stain. Imaging was performed 
with the Zeiss LSM800 confocal laser scanning microscope, and analysis using the ZEN 
software.  
Electron microscopy: Cells were fixed in 2.5 % glutaraldehyde in phosphate buffer, rinsed, 
and post-fixed in phosphate buffered 2% osmium tetroxide. The cells were then stepwise 
dehydrated in ethanol followed by acetone and embedded in LX-112. Ultrathin sections were 
cut and contrasted with uranyl acetate followed by lead citrate. The sections were examined in 
a Hitachi HT7700 transmission electron microscope. 
Real-time quantitative Polymerase Chain reaction (RT qPCR): RT qPCR allows for the 




using the Qiagen RNeasy Plus kit, converted to cDNA and amplified with specific primers and 
the SYBR green method. Applied Biosystems’ StepOne plus instrument was used to analyze 
the samples, and the ΔΔCT method used to examine relative changes in gene expression. 
RNA sequencing and bioinformatic analysis: RNA sequencing was performed by the core 
facility Bioinformatics and Expression Analysis (BEA) at Karolinska Institutet. Details can be 
found in the materials and methods section of the published paper I (Friess et al., 2021). In 
brief, Illumina HiSeq 2000 sequencing system was used, followed by differential gene 
expression analysis with R/Bioconductor. For further analysis and visualization, tools such as 
Gene Ontology (GO), Metascape, Gene Set Enrichment Analysis (GSEA), Transcriptional 
regulatory relationships unraveled by sentence-based text mining (TRRUST) and Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway analysis were used. 
Chromatin Immunoprecipitation (ChIP): ChIP was performed to analyze the interaction 
between specific pulled down proteins with DNA sequences of interest. Using the Diagenode 
iDeal ChIP-qPCR kit, chromatin immunoprecipitation was done after cells were cross-linked 
and fixed, incubating the samples with the respective antibody of interest and finally purifying 
DNA to perform RT qPCR. 
Lysosomal assays: Senescence-associated β-Galactosidase assay using a detection kit 
(Abcam) was performed according to the manufacturer’s instructions. Acridine Orange at a 
final concentration 10 µg/ml was incubated for 20 minutes at 37° C. Fluorescent signal was 
detected by inverted fluorescent microscope Axio Observer 3 (Zeiss) using Zen blue software.  
Mitochondrial assays: Total mitochondrial mass was evaluated using 250 nM MitoTracker™ 
(Invitrogen) fluorescent probe in DMEM for 30 min at 37° C. Signal was detected by inverted 
fluorescent microscope and fluorescent mean and area were analyzed. Production of 
mitochondrial superoxide radical was detected using MitoSox™ (Invitrogen) fluorescent 
probe. 5 µM dye was prepared in HBSS and cells were cultivated for 10 minutes at 37° C. 
Fluorescent signal was detected at λex 535 nm/λem 595 nm by Spark reader (TECAN). 
Hydrogen peroxide at 100 µM for 10 min was used as positive control. TMRE (Invitrogen) 
fluorescent probe at 100 nm concentration in DMEM for 30 min was used to detect changes in 
mitochondrial membrane potential. Fluorescent signal was detected by Spark reader (TECAN) 
at λex 535 nm/λem 595 nm. 
Cell death and Neurotoxicity assay: MN9D dopaminergic neuronal cells were stained with 
CellTracker Green CMFDA (Invitrogen, C7025) and washed, before microglia were plated as 
a direct co-culture. The cells were incubated with LPS for 24h, followed by the DNA stain 
Höchst and then counted regarding nuclear condensation and fragmented nuclei for 
quantification of cell death. Additionally, intracellular ROS production in microglia within this 
direct co-culture set up was analyzed using a general oxidative stress indicator kit. Samples 
were run with the BD LSR2 Cell analyzer and data analyzed using FlowJo (BD Biosciences, 




Migration assay: Macrophages or microglia – naïve or pre-conditioned with other cell types 
– were seeded in medium with 10% serum. Using inserts with 8 µm pores, glioma cell lines in 
medium with 5% serum were placed above the macrophages or microglia, respectively. After 
the indicated time points, cells on the inside of the inserts were removed with a cotton swab. 
Remaining cells were fixed and stained using DAPI, the insert membranes imaged under the 
microscope and counted for absolute number of migrated cells. 
Phagocytosis assays: Uptake of tumor cells, labelled with 1 μM of carboxyfluorescein 
succinimidyl (CFSE), by microglia was measured after 4h of co-culture in a seeding ration of 
1:2. Cells were then removed, stained with CD11b-APC, and analyzed with the BD LSR2 cell 
analyzer and later with FlowJo. Uptake of bacteria was tested using microglia infected with S. 
pneumoniae at a multiplicity of infection (MOI) 10. After co-incubation, 200 µg/ml of 
gentamicin was added to kill extracellular bacteria. Subsequently, cells were lysed with 1% 
filtered saponin after indicated time points. Lysates were diluted 1:10 and 100 µl were plated 
overnight (37° C, 5% CO2). Colony forming units were then counted. Uptake of amyloid-β 
was tested using the Beta-Amyloid (1-42) Aggregation Kit (rPeptide) according to the 
manufacturer’s instructions. Fluorescent signal was detected using Spark reader at λex 430 
nm/λem 485 nm and immunoblot analysis confirmed aggregated protein products. 
Cell cycle analysis: Fixed cells were stained in PBS containing 0.1% (v/v) TritonX-100, 10 
ug/ml of propium iodide and 100 ug/ml of RNase for 15 minutes at 37⸰C. Samples were then 
analyzed with the BD LSR2 cell analyzer and data evaluated using FlowJo (BD Biosciences, 
v10). 
Cell proliferation assay: To measure the proliferation of tumor cells, we used the Click-IT 
EDU Alexa fluor 488 flow cytometry kit (Thermo Fisher, C10420) according to 
manufacturer’s guidelines. Briefly, cells were stained with 10 µM of EdU diluted in culture 
media for 2 hours. Cells were washed, fixed in Click-iT fixative for 15 minutes, and then 
incubated with Click-iT reaction cocktail for 30 minutes. Samples were immediately analyzed 
with the BD LSR2 cell analyzer and later with FlowJo. 
Statistical analysis: Statistical analysis was performed using the two tailed unpaired student’s 
t-test when comparing two separate cell types at a given time point or condition or using two-
way ANOVA when comparing multiple time points or conditions. All values are a mean of, as 
indicated, at least 3 independent experiments ± SEM. Results are considered significant for *p 
< 0.05, **p < 0.01, ***p < 0.001, or n.s., not significant, for the indicated comparison. 
Ethical considerations: These in vitro set ups provide comparatively straightforward ways to 
investigate molecular mechanisms without the need of sacrificing laboratory animals following 
ethical principles of 3R. Future validation of key findings however might call for the 
involvement of animal studies. Human tissue samples from the UK Brain Bank were obtained 





4 RESULTS AND DISCUSSION 
4.1 Paper I – Atg7 deficiency in microglia drives an altered transcriptomic 
profile associated with an impaired neuroinflammatory response
  
It is well established that microglia can display a wide variety of activation states upon reaction 
to different stimuli. Microglia-dependent inflammation-mediated neurotoxicity plays a role in 
neurodegenerative disorders and it is important to identify modulators of such activation states 
to better understand their underlying mechanisms (Sarlus & Heneka, 2017). ATG7, as well as 
other components of the autophagy machinery, has multiple autophagy-independent roles 
(Galluzzi & Green, 2019), some of which include direct or indirect impact on transcription in 
different cell types.   
Reduced Atg7 levels do not prevent autophagy induction in microglia 
To investigate how Atg7 may impact the phenotypic activation of microglia, we used BV2 cells 
with shRNA targeting Atg7. Firstly, we show that this knockdown is stable and shows a 
reduction of approximately 80% in mRNA as well as protein levels, compared to the control 
cell line. This is furthermore confirmed by confocal immunofluorescence imaging. This 
knockdown did not per se incapacitate the cells to undergo autophagy. A reduced, but not 
completely abolished induction was shown by immunoblotting of LC3I versus LC3II. As 
reported for macrophages, Atg7 is not essential for autophagy (Vujić et al., 2021). 
Atg7-deficient microglia show an impaired response to LPS, but not to IL-4 
To test the acquisition of different phenotypes with a knockdown of Atg7, microglia cells were 
treated with either the bacteria-derived endotoxin LPS, or interleukin 4 (IL-4). LPS is a 
commonly used stimulus to induce a pro-inflammatory activation state, while IL-4 is 
considered a non-inflammatory stimulus. LPS-induced activation could be measured by a time-
dependent upregulation of Nos2. However, this induction was significantly less pronounced in 
Atg7-knockdown microglia, suggesting an impaired activation. Interestingly, IL-4 stimulation 
led to an equal upregulation of Arg1 between the two cell lines. Atg7 might therefore be a 
selective modulator of some, but not other microglia activation states. 
Atg7 deficiency drives an altered transcriptome with a reduced immune response 
Based on the results described above, we decided to investigate the transcriptome of cell 
stimulated with LPS. In untreated cells, we found over a thousand differentially expressed 
genes (DEG) between BV2 shAtg7 and control cells. By investigating the GO term annotations, 
we could visualize that a great deal of genes downregulated in Atg7-deficient microglia are 
related to terms such as immune response, cytokine production or antigen processing. Atg7-
deficient cells, that had been stimulated with LPS, showed very similar downregulated DEGs 




response. These results are in line with other publications showing the impact of Atg7 on 
transcriptional regulation and pro-inflammatory cytokines (Wang et al., 2018). 
Reduced NF-κB-dependent signaling and nuclear translocation in Atg7-deficient cells 
NF-κB signaling is known to contribute to the regulation of both innate and adaptive immune 
responses, and its deregulation is associated with the development and progression of 
inflammatory diseases (T. Liu et al., 2017). The pathway consists of multiple transcription 
factor subunits, and we found that Nfkb1 was a significant hit in the TRRUST analysis from 
the RNA-seq results. We further showed that the mRNA levels of several other subunits are 
similar in shAtg7 and control cells, however, we found that there is less nuclear translocation 
of p65 in knockdown cells. This result is supported by other reports showing inhibition of LPS-
induced inflammation via blocking of NF-κB signaling (Hou et al., 2019; Subedi et al., 2019). 
Through ChIP analysis we also showed less enrichment of NF-κB to the Nos2 promotor in 
LPS-treated shAtg7 microglia, providing a possible mechanism explaining our observed 
differences in the pro-inflammatory response. 
Atg7-deficient microglia show reduced neurotoxicity after treatment with a pro-
inflammatory stimulus 
In a functional assay cultured with dopaminergic neurons and stimulated with LPS, microglia 
show a certain degree of neurotoxicity characterized by the production of reactive oxygen 
species (ROS). Here, Atg7-deficient cells showed no significant neurotoxicity towards the 
cultured neurons. Flow cytometry analysis of intracellular ROS showed a robust drop in control 
cells after LPS stimulation, consistent with the cells releasing ROS and therefore contributing 
to oxidative stress in the microenvironment. This drop in intracellular ROS was not observed 
in shAtg7 cells. Taken together, the results presented in this paper show that a reduction in Atg7 
gene expression leads to an altered transcriptome and dampened pro-inflammatory response, 
likely mediated through the NF-κB signaling pathway. This suggests that Atg7 is a selective 






4.2 Paper II/Manuscript – Aged microglia: development of immunosenescence 
without replicative senescence 
Microglia acquire a distinct phenotype and transcriptome signature during aging and 
neurodegeneration, that can at times be associated with cellular senescence (C. E. Cho et al., 
2019; Olah et al., 2018). With conflicting results on microglia aging in vitro versus in vivo, 
such as differences in telomerase activity, we identified a need for a model of long-term 
cultivated microglia cells to investigate transcriptomic changes and possible cellular 
senescence to gain a better understanding into physiological aging in microglia. 
Long-term cultivated microglia are not associated with age-related cellular senescence 
Cellular senescence can present as many factors, such as cell cycle perturbations or abnormal 
organelle morphology. In our model of culturing microglia for at least 100 days, we observed 
no difference in cell cycle phase distributions as compared to early passages, further referred 
to as young cells, and genes encoding for cell cycle repressors such as Cdkn2a and Cdkn1a 
were even downregulated in aged cells. Likewise, we found no observable difference in 
organelle morphologies in electron microscopy pictures, mitochondrial membrane potential, or 
staining for β galactosidase, a biomarker used for cellular senescence. We therefore conclude 
that these in vitro aged microglia cells do not enter a senescent state. 
Long-term cultivation of microglia induces a distinct transcriptomic profile associated 
with reduced expression of immune-related genes 
High-throughput bulk RNA-seq revealed a distinct transcriptomic signature in aged versus 
young cells, including over 1000 downregulated and over 600 upregulated genes in aged cells. 
GO term analysis of genes downregulated in aged microglia cells presented clusters associated 
with response to external stimuli, cytokine production, mediated immunity, and signaling 
pathways such as NF-κB. GO terms clustering upregulated genes on the other hand included 
telomere maintenance, which were unexpected regarding an aged phenotype. We could indeed 
confirm an increased length of telomeres in the aged cells. TRRUST analysis on the subset of 
downregulated genes in aged cells resulted in hits on transcription factors SPI1/PU.1, playing 
a crucial role in the development and homeostasis of microglia, as well as RELA/p65 and 
NFKB1, implicated in the regulation of immune response genes (Holtman et al., 2017). 
Long-term cultivated microglia share transcriptomic similarities with primary microglia 
derived from aged mice 
To evaluate the relevance of this proposed model, transcriptomic signatures were compared 
with studies on primary cells extracted from aging mice. We found an overlap of 140 genes, of 
which several were associated with a database of murine age-related genes, the AgingAtlas 
(Aging Atlas Consortium et al., 2021). We suggest that primary cells derived from aged 
animals are likely not completely unchallenged or primed in life, and therefore also compared 





Long-term cultivated microglia show reduced neurotoxicity, but efficient uptake of 
amyloid-β 
To investigate potential functional disturbances correlating with the significant downregulation 
of immune-related genes in the aged microglia, we carried out functional assays on 
neurotoxicity and the uptake of amyloid-β. The disrupted clearance of amyloid-β plaques and 
its associated neurotoxicity in the aging brain are hallmarks of neurodegeneration, specifically 
AD. In our model after co-culture with dopaminergic neurons, aged microglia stimulated with 
LPS resulted in decreased levels of neurotoxicity as compared to young LPS-treated microglia. 
We could not observe a difference in the uptake of amyloid-β, suggesting there may be cues 
from the microenvironment of the aging brain missing to induce such dysfunction or that the 
toxic accumulation of protein aggregated precedes an immunosenescent or primed-like 
microglia phenotype in vivo.  
In summary, long-term cultivated microglia may present a novel model of aging cells that do 
not enter a senescent state yet show similarities to primary cells from aged animals. Our data 
indicate that such aged microglia have a reduced inflammatory response to stimuli, but the 
correlations between aging, pathological changes in neurodegeneration and acquisition of 





4.3 Paper III – Inhibition of microglial EZH2 leads to anti-tumoral effects in 
pediatric diffuse midline gliomas 
DIPG are highly aggressive pediatric brain malignancies, characterized by H3K27M 
mutational status which leads to a global loss of H3K27me3 expression (Khuong-Quang et al., 
2012). In preclinical models, DIPG can be targeted by inhibiting the histone methyltransferase 
EZH2, even though in vitro experiments on DIPG cells yielded little to no effect on these cells 
(Wiese et al., 2016). The TME can be highly variable between different types of tumors and 
contribute to disease onset as well as progression and targeting tumor-associated microglia 
could provide further insight into the mechanisms behind the use of EZH2 inhibitors.  
Pro-tumoral microglia activation is linked to a short-term decrease in H3K27me3 
First, we examined the activation of microglia as mediated by the different glioma cell lines 
used in this study. DIPG and pHGG cell lines with and without the H3K27M mutation, 
respectively, could both induce a pro-tumoral microglia phenotype as seen by increased tumor 
migration after co-culture with BV2 microglia as well as a decrease of Nos2 gene expression 
in the microglia cells. Additionally, we found a transient downregulation of H3K27me3 
expression in microglia cells after 4h of co-culture with both cell lines. The expression levels 
returned to baseline expression after 24h. Such mechanisms of epigenetic control mediated by 
the tumor could be required to reprogram microglia towards a pro-tumoral activation state 
(Cheray & Joseph, 2018). 
Repression of EZH2 in pHGG has no impact on proliferation or cell death 
Next, we tried to understand if EZH2 inhibitors were mediating their reported in vivo effects 
through targeting the tumor cell or the TME. To achieve that, we first targeted the EZH2 gene 
expression by siRNA specifically in the tumor cells. We found that neither cell proliferation 
nor cell death, measured by proliferating cell nuclear antigen (PCNA) and markers of apoptotic 
cell death, were affected in DIPG or pHGG cells when EZH2 was repressed. This suggests that 
genetic inhibition of EZH2 in glioma cells has little to no effect on their basic cellular functions. 
Repression of Ezh2 in BV2 microglia leads to an anti-tumoral activation state 
We then repressed Ezh2 specifically in BV2 microglia cells. Knockdown of Ezh2 in microglia 
led to a significant decrease of global H3K27me3 as expected. Gene expression of Nos2 was 
increased by more than 3-fold, suggesting a reprogramming of microglia to a more anti-tumoral 
state when Ezh2 was repressed in these cells. ChIP analysis showed a decrease of H3K27me3, 
and an increase of H3K27ac on the Nos2 promotor, with both modifications being associated 
with a higher transcriptional activity. Investigation of the LPS-induced anti-tumoral cytokine 
Il1b showed increased gene expression after Ezh2 knockdown in microglia, further supporting 
that these cells acquire a distinct phenotype by the repression of Ezh2. To test this hypothesis 
in a functional manner, we conducted invasion assays, measured phagocytotic activity and 
glioma cell death. We found that in both cell lines, as well as in primary patient-derived DIPG 




Phagocytosis, as well as glioma cell death, were on the other hand significantly increased after 
the genetic knockdown, further supporting that microglia become anti-tumoral when Ezh2 is 
repressed. Taken together, our results support the hypothesis that EZH2 inhibition in vivo leads 
to reduction in tumor growth not by acting upon the glioma cells per se, but on the epigenetic 
landscape of microglia in the TME. These epigenetic changes result in a pro-tumoral 
reprogramming of microglia independent of the H3K27M status of the glioma cells. Overall, 
this argues for the role of microglia, and potentially other cell types within the TME, to have 






4.4 Paper IV/Manuscript – Understanding if the presence of peripheral 
macrophages in the context of glioblastoma influences the tumor-
associated microglial phenotype 
Glioblastoma carrying an IDH1 mutation are associated with less infiltration and a generally 
better prognosis compared to IDH1 wildtype tumors (Price et al., 2017). While microglia in the 
TME have been shown to be rather pro-inflammatory, infiltrating macrophages show a more 
upregulated anti-inflammatory transcriptome, which could explain the correlation between 
tumor-associated and macrophage amount with overall survival independently of IDH-status 
(Poon et al., 2019).  A higher ratio of microglia was furthermore found to be beneficial for 
survival in glioblastoma, suggesting distinct roles of microglia and macrophages in the TME 
(Woolf et al., 2021). We hypothesized that the infiltration of macrophages impacts microglia, 
which initially exert pro-inflammatory or anti-tumoral functions, to create a tumor-supportive 
TME.  
The presence of TAM macrophages as a negative prognostic marker in glioblastoma 
The presence of an IDH1 mutation is associated with a better overall survival and carrying this 
mutation can be a prognostic marker for glioblastoma. Furthermore, patient samples carrying 
the IDH1 mutation showed a low gene expression of the macrophage markers ITGA4 and 
CD163, while having a higher gene expression for microglia marker P2RY12. Overall survival 
in glioblastoma was positively correlated with the expression of P2RY12, while expression of 
CD163 and ITGA4 on the other hand is in negative correlation with overall survival.  
Glioblastoma carrying IDH1 mutation induces an anti-tumoral microglial activation 
state 
We identified the IDH1 mutational status of the cell lines used by protein analysis via Western 
blotting. U87 MG IDH1R132H, as characterized, carried the IDH1 mutation, while U87 MG, 
U251 and U1242 did not show any sign of the mutation. The latter present glioblastoma cells 
with higher rates of aggression and invasion. We utilized glioma cell migration as a functional 
assay to test the result of a potential activation of microglia. In IDH1 mutant glioblastoma cells, 
a significant reduction of migration as compared to wildtype glioblastoma cells was observed. 
U1242 cells showed slightly less migration after co-culture with microglia, however, this effect 
was not as strong as seen in IDH1 mutant cells. 
The presence of microglia decreases proliferation rate of glioblastoma cells  
We then analyzed proliferation rates of the glioblastoma cell lines after co-culture with 
microglia cells and found a decrease for both wildtype and IDH1 mutant cells. Preliminary data 
of one replicate suggests a similar trend for U251 and U1242 cell lines. We preliminarily 
conclude that microglia exert an anti-tumoral phenotype towards all glioblastoma cell lines, 





Microglia and macrophages increase anti-tumoral gene expression with glioblastoma 
cells 
Microglia show an increased gene expression of Tnf and Nos2 after co-culture with some, but 
not all glioblastoma cell lines. These results represent at the time three independent replicates 
and do not show statistical significance. However, macrophages present upregulated gene 
expression in a similar manner and co-culture with the highly aggressive cell line U1242 leads 
to significant increase of Tnf and Nos2. Further characterization of the anti-tumoral activation 
of both microglia and macrophages in the presence of glioblastoma will be performed. 
Presence of macrophages induces a pro-tumoral microglial activation state in co-culture 
with glioblastoma cells 
In an effort to model the presence of both, microglia and macrophages, in the TME of 
glioblastoma, we performed a triple co-culture exposing microglia to both macrophages and 
glioblastoma. We then transferred these primes microglia to perform a sequential migration 
assay with glioblastoma cells to analyze the impact of both macrophages and glioblastoma 
present on microglia-mediated tumor cell migration. Interestingly, we found that in the 
described set up, microglia seemed to activate towards a more pro-tumoral phenotype, 
represented by increased tumor cell migration and upregulation of Tnf and Mmp14. These 
results represent only one replicate at this point and are currently being repeated. 
Taken together, preliminary results of our currently ongoing research work suggest that 
microglia present an initial anti-tumoral phenotype when cultured with only glioblastoma cells. 
In the additional presence of macrophages however, microglia seemingly transition towards a 
pro-tumoral phenotype, increasing tumor migration and upregulating a pro-tumoral gene 





5 CONCLUSIONS AND POINTS OF PERSPECTIVE 
The here presented studies and manuscripts provide novel insights into microglial activation 
and function within different contexts.  
▪ Knocking down Atg7, otherwise implicated in the process of autophagy, highly affects 
the transcriptomic signature of microglia and shifts them towards a reduced immune 
response profile. This regulation is likely mediated via the NF-κB signaling pathway. 
 
▪ Atg7-deficient microglia cells are impaired when responding to a challenge with a pro-
inflammatory stimulus and show a distinct, decreased function in assays assessing 
neurotoxicity. This diminished response was not observed after an anti-inflammatory 
stimulus, suggesting a selected modulation. 
 
▪ In the context of aging, we aim to provide a novel model of long-term cultivated 
microglia that show transcriptomic similarities with primary microglia extracted from 
aging mice. We show that these in vitro aged cells have a distinct transcriptomic 
signature, including downregulation of immune-related genes and pathways, but do not 
enter cellular senescence.  
 
▪ Inhibition of the histone methyltransferase EZH2 in the DIPG TME does not affect the 
tumor cells or their ability to recruit TAMs per se, but rather leads to an anti-tumoral 
activation state of the microglia. This highlights the importance of microglia, and the 
heterogeneity of the TME, as a potential therapeutic target in pHGG.  
 
▪ Preliminary experiments show that microglia exert anti-tumoral activation towards 
glioblastoma as represented by reduced tumor cell migration. This is potentially 
switched towards a pro-tumoral activation when microglia are exposed to not just 
glioblastoma cells, but also macrophages, suggesting that infiltrating immune cells 
impact the TME and potentially reprogram microglia. However, more work remains to 
be done with this project. 
In summary, we addressed research questions regarding the inflammatory response of 
microglia, a potential new model for cellular immunosenescence and the role of microglia in 
the TME of glioblastoma. Such examples and follow-up studies will be beneficial in 
elucidating the role of microglia, and macrophages, and how they adapt their functions 
depending on stimuli from their microenvironment by modulating the underlying 
transcriptomics signatures. To really bring these findings into the clinic however, a lot of work 







Regarding future perspectives, one subject of research to come will surely be to understand the 
unique features and functions of microglia in their distinct activation types. Especially 
advances in fields such as single cell RNA sequencing hold a great deal of information 
describing new transcriptomically distinct population of microglia. However, more effort 
should be invested into elucidating how these manifold subsets, or even subtypes, functionally 
differ from each other to draw useful conclusions. Many studies are conducted on microglia in 
the context of different diseases or disorders, yet with such plastic cells it remains often difficult 
to investigate the exact time points or circumstances that are crucial for microglia activation 
states. Within the TME especially, it remains unclear how the different cell types involved 
really communicate with each other, including the mechanisms behind microglia and 
macrophage reprogramming.  
Secondly, we need to gain further understanding of how microglia activation states are 
regulated. Knowledge of how to potentially manipulate a microglia cell in vivo into, for 
example, a more phagocytic active cell taking up and clearing higher loads of accumulated 
neurotoxic protein aggregates, could hold enormous potential for clinical advances. Signals 
that drive cellular change are often well established. However, signaling cascades with their 
complex interconnections between different pathways and interactions between regulatory 
transcription factors are often only described on a high level with the need for further clarifying 
research. Other regulatory components such as epigenetic changes or post-translational 
modifications, impacting how microglia cells function and communicate with other cell types, 
could also serve as promising new targets for therapeutics. The potential impact of external 
challenges on microglia activation states, such as how stress or infections throughout the span 
of a life could prime or affect microglia towards certain functions in old age or during 
neurodegeneration, is an additionally interesting aspect of future research. Another example is 
addressed by newly emerging research on the interaction of the gut microbiome with the CNS, 
contributing findings on how the gut-brain-axis can be linked to microglia development and 
function and providing exciting new hypotheses and insights into alternative modulators of 
microglia activation states (Abdel-Haq et al., 2019).  
A third perspective addresses potential technical drawbacks and challenges that are present in 
the field of microglia research. As with any experiments, especially in the neurosciences, it is 
important to be aware of the limitations of cell culture lacking the structural and chemical 
environment of other cell types involved. With microglia in particular, we know that they 
exhibit different transcriptomic signatures between ex vivo and in vitro, as well as differences 
depending on the brain region, independently of other stimuli (Gosselin et al., 2017; Grabert et 
al., 2016). However, basic findings can still be established in simple set ups and, if applicable, 
validated in other models. With advances in scRNA-seq and similar methods, more and more 
clusters and transcriptionally distinct cell groups are analyzed, yet their implications are mostly 
unclear. Methodological hurdles present furthermore in standardizing sample preparation and 
extraction, sequencing protocols, and particularly the bioinformatics pipelines and analysis. 
And lastly, even though key proteins in research findings might be evolutionarily conserved, 




example, research in microglia aging, one needs to keep the vastly different life expectancies 
or natural processes of aging in mind. Finding novel models and characterizing them 
extensively to evaluate their use if therefore crucial to confidentially translate in vitro into in 
vivo findings. 
Finally, points of perspectives include the chances and challenges of therapeutic advances in 
the field of microglia research. Understanding the underlying mechanisms of how microglia 
activation states are induced and regulated could hold the key in finding novel treatment 
approaches to ultimately bring basic research findings into the clinics for the patients’ benefit. 
Many approaches to, for example, deplete microglia are either not selective enough, result in 
other deficiencies or lack efficiency and CSF1R inhibitors seem to propose a somewhat 
promising route to study microglia (Green et al., 2020). It will be helpful to stop addressing 
microglia as a single entity and consider their vast heterogeneity to be able to target specific 
populations when needed. The reprogramming of such cells will likely be more promising and 
successful than simply depleting them, however, this requires in-depth knowledge about 
regional, spatial, and functional heterogeneity of microglia across the healthy lifespan, as well 
as in the context of diseases. 
The current microglia research field is as active as the cells themselves, and I am excited to see 
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